Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PR Newswire WALTHAM, Mass., Dec. 10, 2024 -- SIGNAL-AA demonstrated encouraging...
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 7, 2024 -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB...
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 PR Newswire WALTHAM, Mass., Oct. 14...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.13 | -3.77906976744 | 3.44 | 3.77 | 3.02 | 661964 | 3.35913924 | CS |
4 | -23.54 | -87.6722532588 | 26.85 | 28.66 | 3.02 | 709611 | 6.4197786 | CS |
12 | -41.58 | -92.6264201381 | 44.89 | 53.17 | 3.02 | 293762 | 14.29751724 | CS |
26 | -12.24 | -78.7138263666 | 15.55 | 53.79 | 3.02 | 198495 | 21.01936821 | CS |
52 | -12.93 | -79.618226601 | 16.24 | 53.79 | 3.02 | 149479 | 21.35556503 | CS |
156 | -12.93 | -79.618226601 | 16.24 | 53.79 | 3.02 | 149479 | 21.35556503 | CS |
260 | -12.93 | -79.618226601 | 16.24 | 53.79 | 3.02 | 149479 | 21.35556503 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales